
==== Front
Sci Rep
Sci Rep
Scientific Reports
2045-2322
Nature Publishing Group UK London

92293
10.1038/s41598-021-92293-x
Article
ELV-N32 and RvD6 isomer decrease pro-inflammatory cytokines, senescence programming, ACE2 and SARS-CoV-2-spike protein RBD binding in injured cornea
Pham Thang L. 1
He Jiucheng 1
Kakazu Azucena H. 1
Calandria Jorgelina 1
Do Khanh V. 1
Nshimiyimana Robert 2
Lam Ting F. 2
Petasis Nicos A. 2
Bazan Haydee E. P. richardchavez@example.net

1
Bazan Nicolas G. richardchavez@example.net

1
1 grid.279863.1 0000 0000 8954 1233 Neuroscience Center of Excellence, School of Medicine, Louisiana State University Health New Orleans, 2020 Gravier St., Ste. D, New Orleans, LA 70112-2223 USA
2 grid.42505.36 0000 0001 2156 6853 Department of Chemistry and Loker Hydrocarbon Research Institute, University of Southern California, Los Angeles, CA USA
17 6 2021
17 6 2021
2021
11 127874 8 2020
4 6 2021
© The Author(s) 2021
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection that causes coronavirus disease 2019 (COVID-19) has resulted in a pandemic affecting the most vulnerable in society, triggering a public health crisis and economic collapse around the world. Effective treatments to mitigate this viral infection are needed. Since the eye is a route of virus entrance, we use an in vivo rat model of corneal inflammation as well as human corneal epithelial cells (HCEC) in culture challenged with IFNγ as models of the eye surface to study this issue. We explore ways to block the receptor-binding domain (RBD) of SARS-CoV-2 Spike (S) protein to angiotensin-converting enzyme 2 (ACE2). We found that the lipid mediators, elovanoid (ELV)-N32 or Resolvin D6-isomer (RvD6i) decreased the expression of the ACE2 receptor, furin, and integrins in damaged corneas or IFNγ-stimulated HCEC. There was also a concomitant decrease in the binding of Spike RBD with the lipid treatments. Using RNA-seq analysis, we uncovered that the lipid mediators also attenuated the expression of pro-inflammatoy cytokines participating in hyper-inflammation and senescence programming. Thus, the bioactivity of these lipid mediators will contribute to open therapeutic avenues to counteract virus attachment and entrance to the body.

Subject terms

Drug discovery
SARS-CoV-2
http://dx.doi.org/10.13039/100000053 National Eye Institute EY031031 EY019465 Kakazu Azucena H. Bazan Haydee E. P. issue-copyright-statement© The Author(s) 2021
==== Body
Introduction

In December 2019, a new infectious respiratory disease (Coronavirus disease 2019, COVID-191) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged2,3, quickly becoming a pandemic and a global threat to public health. The virus has a single-stranded RNA with a 30 kb genome that encodes the Spike (S) protein containing a receptor-binding domain (RBD) for the angiotensin-converting enzyme 2 (ACE2) receptor4. Furthermore, the S protein contains cleavage sites for proteases FURIN and transmembrane serine protease 2 (TMPRSS2) that allow viral cell entrance5. Cells from the eye surface, lung alveoli, GI tract, among others, co-expressed Ace2 and Tmprss2 genes6.

The eye surface is a route of SARS-CoV-2 entrance7,8. One of the consequences of this viral infection is the inflammatory response in affected individuals, particularly in the aging population. Some lipid mediators that modulate inflammatory responses have been hypothesized to counteract COVID-19 pathology9–11. Lipid mediators facilitate debris clearance and antagonize pro-inflammatory cytokines by fostering inflammation resolution12,13. Here, we study lipoxin A4 (LXA4) derived from ω-6 arachidonic acid14, the R,R stereoisomer of Neuroprotectin D1 (NPD1)15,16, and Resolvin D6-isomer (RvD6i)17 derived from ω-3 docosahexaenoic acid (DHA), and Elovanoid (ELV)-N32. RvD6i and ELV-N32 are new lipid mediators discovered in our laboratory. Elovanoids are named because they are derived from very long chain polyunsaturated fatty acid products of the Elongation of Very Long Chain fatty acids protein 4 (ELOVL4) enzyme18,19 with pro-homeostatic and neuroprotective bioactivity13,17,18. Here, we show that ELV-N32 and RvD6i selectively decrease the ACE2 receptor expression and S protein RBD binding to the cornea stroma in an in vivo rat model of eye injury. We confirm that Ace2 is an interferon-stimulated gene in human corneal epithelial cells (HCEC), a mechanism that would enhance the infectivity of SARS-CoV-220. Therefore, we use HCEC in culture challenged with IFNγ to demonstrate that ELV-N32 or RvD6i exert blockage of ACE2 expression and RBD binding, hyper-inflammation, senescence programming, and pro-inflammatory cytokines.

Results

Lipid mediators decrease cornea injury-induced expression of ACE2 and binding of spike protein RBD

The SARS-CoV-2 receptors, including ACE2 and DPP45, and the host proteases for the S protein, including FURIN6 and TMPRSS2, are expressed in the cornea (Fig. 1a), indicating that it is a potential site for SARS-CoV-2 entrance, in agreement with clinical studies showing infected patients' epiphora, conjunctival congestion, or chemosis21. SARS-CoV-2 triggers lung injury and a systemic dysfunction of the inflammatory-immune system reflected in the cytokine storm22,23. We found that our cornea injury model recapitulates inflammatory-immune system dysfuctions24, including ACE2 receptor expression upon injury. To identify mediators that modulate these responses and to understand consequent mechanisms, we tested the following lipid mediators: LXA4, ELV-N32, RvD6i, and NPD1 (Fig. 1b,c). LXA4, ELV-N32, and RvD6i decrease ACE2 abundance and gene expression levels (Supplementary Fig. S1) to non-injured tissue, while NPD1 shows no consistent effect (Fig. 1d and Supplementary Fig. S1). Alexa 594-RBD displayed remarkable binding to the injured corneal stroma, and LXA4, ELV-N32, and RvD6i counteracted these injury-induced effects; however, NPD1 did not (Fig. 1e–h). Thus, there is a correlation between changes in the ACE2 receptor and RBD binding in the cornea after injury and lipid treatment. Although NPD1 decreased Dpp4 expression (Supplementary Fig. S1), it failed to inhibit the binding of the RBD to the damaged cornea. In addition, a recent publication reported that the SARS-CoV-2 virus could not enter cells expressing DPP4 as efficiently as cells expressing ACE24. Therefore, we suggested that the RBD binding of the S protein was to ACE2 rather than to DPP4. Interestingly, most of the RBD was detected in the stroma and neutrophils, and inflammatory cells labeled with CD68 showed co-localization with RBD (Supplementary Fig. S2b). The population of these two cell types is increased in the cornea after injury and diminished by the lipid mediator treatments (Supplementary Fig. S2c).Figure 1 Selective lipid mediators reduce cornea injury-induced expression of ACE2 and binding of Alexa 594-RBD. (a) Expression of Ace2, Dpp4, furin and Tmprss2 in the uninjured rat cornea. Left: representative immunofluorescence imaging. DAPI stains nuclei (blue). Immunofluorescence shows ACE2 expressed in the epithelium and stroma. Right: RNA-seq data. (b) Experimental design. After alkali burn, rats received eye drops of lipid mediators or vehicle 20 μL/eye, 3 times/day for 14 days (double-blinded). ACE2 expression was assayed at day 14 after injury ± lipids treatment. At day 15, rats were treated with Alexa 594-RBD (1 µg/eye, 3 times) and corneas examined a day later. (c) Lipid mediators studied. The chirality in all figures of RvD6i and NPD1 used in this study had the R,R stereochemistry. (d) ACE2 abundance before and after injury ± lipids using Jess capillary-based Western Blot system (Protein Simple). ACE2 densitometry normalized to GAPDH in the same capillary to minimize errors. Data is from one rat cornea for each data point (N = 4). The p-values of ANOVA-post hoc Dunnett's multiple comparisons test with vehicle as reference are shown. Mean and SD are depicted as the lines. (e) Illustration showing corneal analysis by wholemount (x and z planes—orange color) and cross-section (x and y planes—blue color). (f) Wholemount images of binding of Alexa 594-RBD in corneas after injury and treatments. The control cornea (no-injury) has very low Alexa 594-RBD signal, while the injured cornea shows intense fluorescence. LXA4, ELV-N32, and RvD6i decrease Alexa 594-RBD binding while NPD1 fails. (g) Cross-section images of the same corneas shown in (f). The green lines were added to separate the epithelium from the stroma. Most of Alexa 594-RBD signal was found in the stroma. (h) Quantification of Alexa 594-RBD positive cells. Each data point represents number of cells/cross-section image. Values are means ± SD and p-values calculated by ANOVA-post hoc Dunnett's multiple comparisons test with vehicle as reference (4 images/cornea and 4 rat corneas/condition). The map of image capture is shown in Supplementary Fig. S2.

Lipid mediators disrupt the ACE2 upregulation, hyper-inflammation, senescence programming, and pro-inflammatory cytokines in the injured cornea in vivo

RNA-seq analysis 14 days after injury with and without treatment (Fig. 1b) revealed well-clustered transcriptional profiles in each treated group (Fig. 2a). In principal component analysis (PCA) plots (Fig. 2a), the transcriptomic profile of non-injured corneas, control (red), and injured corneas treated with vehicle (green) were separated well. Topical treatment with lipid mediators shows profiles closer to control corneas than to vehicle-treated corneas. ELV-N32 (pink) was the nearest to the normal cornea, follow by RvD6i, LXA4, and NPD1. DEseq2 analysis allows comparison of all treated groups as well as control corneas to vehicle as a reference. Upregulated genes in vehicle-treated injury corneas revealed differences among treatment with lipid mediators, as depicted in Venn diagrams (Fig. 2b). Since NPD1 failed to decrease the ACE2 expression and RBD binding upon injury (Fig. 1d–h), we focused on the groups of shared genes (red circles) between control-LXA4-ELV-N32-RvD6i (450 genes including Ace2) and control-ELV-N32-RvD6i (737 genes). The EnrichR generating-KEGG pathway analysis of these two data sets revealed cytokines and senescence-related pathways (Fig. 2c) with significant false discover rate (FDR) values. On the other hand, IPA analysis of these two gene set combinations (1187 genes in total in Fig. 2b) predicted several cytokines as upstream regulators of increased Ace2 expression after injury (Fig. 2d). In addition to cytokines, the senescence maker CDKN2A (p16/INK4) and the NFkB (complex) and its correlated genes were predicted to be inducers of Ace2 (Fig. 2d). The RNA-seq analysis of the Cdkn2a gene (Fig. 2e), the IPA inhibition score and p-value of this gene (Fig. 2f), and the NFKB complex (Fig. 2g) confirm that ELV-N32 and RvD6i are the most potent inhibitors of these pathways.Figure 2 Selective lipid mediators disrupt ACE2 upregulation and injury-mediated hyper-inflammation, senescence, and pro-inflammatory cytokines components. (a) PCA plot of RNA-seq data. Rat corneas were analyzed at day 14 after injury ± treatments (Fig. 1b). Each data point represents one animal (N = 5/group, except LXA4 with N = 3 and control with N = 6). The eclipse of 95% confidence interval was used to group data points from the same set of treatment. (b) Venn diagram of significant genes (FDR < 0.05) upregulated by the vehicle treatment of injured corneas (RNA-seq data set was analyzed using DEseq2 with vehicle injured corneas as reference). The negative log2 fold change genes (upregulated by vehicle) with FDR < 0.05 were used. We excluded NPD1 because it failed to decrease Ace2 expression upon injury (Fig. 1d). The groups of shared genes between control-LXA4-ELV-N32-RvD6i and control-ELV-N32-RvD6i are depicted in red circles. (c) The KEGG-pathway enrichment networks obtained from EnrichR tool of selected genes from (b). Bars were sorted by p-value. The length of the bar represents the significance of the pathway, while the lighter the color, the higher the significance. The number shows amount of genes from denoted group that are enriched in each pathway. (d) IPA upstream regulator analysis of significant genes vs. vehicle (injury) group. There are proteins with negative activation z-score compared to vehicle group (blue color). Among those are CDKN2A and NFkB (complex). (e) RNA-seq normalized counts of Cdkn2a gene that encodes the senescence key-marker p16INK4a; ELV-N32 decrease its expression. Data correspond to one cornea for each data point and is presented as mean ± SD. The p-values were analyzed by ANOVA-post hoc Dunnett's multiple comparisons test with vehicle as reference. The normalized counts were used for analysis. IPA scores for CDKN2A (f) and NFkB (complex) (g) upstream regulators. The left y-axis is the inhibition z-score, while the right y-axis e is − log10 of p-value. The cutoff line for p-value is < 0.05.

Lipid mediators counter-regulate pro-inflammatory cytokines, NFkB/inflammation, and senescence-associated secretory phenotype after cornea injury

Since upregulated Ace2 gene expression is caused by the action of cytokines, p16INK4a, and NFkB, we targeted genes regulated by these inducers. Thus, in the injured cornea, we explored: (i) activated cytokines found in the serum of SARS-CoV-2 patients22, (ii) senescence-associated secretory phenotype (SASP) genes25, and (iii) NFkB/inflammation genes found in lung biopsies of SARS-CoV-226. The Venn diagram showed several genes shared by the three inducers (Fig. 3a). The Heatmap indicated that 51 injury-upregulated genes were counteracted by the lipid mediators (Fig. 3b). All 51 of these genes belong to the cytokines and SASP-related genes (Supplementary Fig. S3a). The plot for each specific gene is provided in Supplementary Figs. S3–S5. Among those genes, Cxcl10, Il1r1, and Hgf (Supplementary Figs. S3c, S4, and S5) are related to SARS-CoV-2 severity27, while genes related to metalloproteinases, such as Mmp9 (Supplementary Fig. S4), Mmp3, Mmp12, and Timp1 (Supplementary Fig. S5), are increased after coronavirus infection and involved in the degradation of the extracellular matrix, which facilitates hyper-inflammation, leukocyte infiltration, and ECM remodeling and fibrosis28,29. Further, transient receptor Trpc6 (Supplementary Fig. S4) is a component of chronic obstructive pulmonary disease development30.Figure 3 Lipid mediators down-regulate injury-induced gene expression of NFkB/inflammation, senescence-associated secretory phenotype, and pro-inflammatory cytokines after cornea injury. (a) Venn diagram of cytokines, SASP, and NFkB inflammatory genes upregulated by injury. (b) Heatmap of normalized counts data. Each small square represents data from one cornea. There are 51 genes increased by injury, and most are inhibited by ELV-N32 and RvD6i treatment. (c) The ArchS4 human tissue analysis prediction for the 51 genes. The length of the bar represents the significance of the gene set in the tissues, while the lighter the color, the higher the significance. The numbers show the genes from the denoted group enriched in each pathway. (d) Scatter plots of Il1b, Il6, and Vegfa genes. (e) Scatter plots of genes that encode proteins that target RGD. The p-value of ANOVA-post hoc Dunnett's multiple comparisons test with vehicle as reference are shown. Mean and SD are depicted as the lines. The normalized counts were used for analysis. The protein level of IL1B and VEGF were confirmed using Jess capillary-based western assay (Supplementary Fig. S8).

Using pathway analysis, we found similar pathways to those found in the entire transcriptome (Fig. 2c and Supplementary Fig. S3a). Employing the EnrichR–Archs4 human analysis tissue database, we found that the 51 genes are more abundant in the omentum and lung (bulk tissue) (Fig. 3c). This suggests that genes detected in the injured cornea might recapitulate changes in gene expression that occur after lung injury. Three targeted cytokines, Il1b, Il6, and Vegfa genes, are plotted in Fig. 3d. Our data showed that these genes were upregulated by the injury, and the administration of LXA4, ELV-N32, or RvD6i reduced their expression. We also focused on integrin genes since the Spike protein contains an arginine-glycine-aspartic acid motif in the RBD site that is recognized by some integrins as a potential receptor of SARS-CoV-231,32. Six integrins, which have the RGD binding domain in the heterodimer conformation, are increased after injury and decreased by some of the lipid mediators (Fig. 3e). Among these genes, Itga5 and Itgb1 are of interest since their specific blocker ATN-161 greatly attenuates the SARS-CoV-2 infection in vitro33, and their expression is significantly decreased by ELV-N32 and RvD6i.

Lipid mediators attenuate IFNγ-specific induction of ACE2 expression, RBD exposure, and senescence programming in HCEC

Based on the IPA prediction that upstream regulators of Ace2 targeted some cytokines, we treated HCEC with IL1β, IL2, IL6, IL8, IFNγ, IFNα, IFNε, or TNFα at 1, 10, and 100 ng/mL concentrations. IFNγ and IFNα were the only cytokines to activate Ace2 expression, with IFNγ being the more potent of the two, inducing ACE2 expression at 1 ng/mL. Therefore, we chose IFNγ as the inducer of Ace2 in the HCEC experiment (Fig. 4a and Supplementary Fig. S6). Following Ace2 expression by dd-PCR that provides absolute quantification at the transcription level, ELV-N32 and RvD6i markedly attenuated IFNγ-triggered Ace2 activation while LXA4 did not have any effect. (Fig. 4b). In addition, IFNγ stimulates the overexpression of senescence programming genes Cdkn2a (p16INK4a) and Mmp1. ELV-N32, RvD6i, and NPD1 decrease Cdkn2a activation to control values, but LXA4 does not. IFNγ-stimulated Alexa 594-RBD binding was analyzed by Imaris (Fig. 4c and Supplementary Fig. S7) correlates with increased ACE2 expression (Fig. 4b). ELV-N32, RvD6, and NPD1 decrease IFNγ-stimulated RBD binding (Fig. 4c). Following IFNγ-stimulated RBD binding to ACE2, induction of senescence programming genes Cdkn2a (p16INK4a) and Mmp1, and SASP secretome activation (β-Gal staining) takes place. These events are blocked by ELV-N32, RvD6i, and NPD1 but not by LXA4 (Fig. 4d).Figure 4 Lipid mediators attenuate IFNγ-induced ACE2 expression, senescence programming, and binding of Alexa 594-RBD in human corneal epithelial cells (HCEC). (a) Among several cytokines tested only IFNγ and α, induces ACE2 expression in HCEC (6 h after stimulation, analyzed by dd-PCR). (b) Effect of lipid mediators on gene expression of Ace2, Cdkn2a, and Mmp1 of HCEC after adding IFNγ (100 ng/mL). ΔΔCT normalized fold change was used. p-values of statistical t test analysis in comparison to vehicle group are shown. Mean and SD are shown as the lines. (c) Alexa 594-RBD binding in HCEC. IFNγ (100 ng/mL) and lipid mediators (200 nM) were added to the HCEC for 12 h. Alexa 594-RBD (0.5 ng/well) was then added and images taken 24 h after. Fifteen images/condition analyzed. Representative images are shown (left side), and the Imaris based calculation was plotted (right-hand side). Data are presented as single image/each data point. The p-value of ANOVA-post hoc Dunnett's multiple comparisons test with vehicle as reference. Mean and SD are shown as the lines. (d) SASP Secretome (β-Gal staining) of HCEC 24 h after IFN-γ challenge and ± lipid mediators. Each point represents one image. The p-value of ANOVA-post hoc Dunnett's multiple comparisons test with vehicle as reference are shown. Mean and SD are shown as the lines. Representative images for each condition are in the right panel.

Discussion

The severe COVID-19 outbreak is characterized by hyper-inflammation and "cytokine storm," therefore, the management of local and systemic inflammatory response to SARS-CoV-2 may be as important as antiviral therapies. Among anti-inflammatory agents, the specialized pro-resolvin lipid mediators (SPMs), such as LXA4, NPD1 and RvD6i, facilitate the clearance of cell debris and counteract the action of pro-inflammatory cytokines in a process called "inflammation resolution without any immunosuppressive complications"34. Recently, SPMs were hypothesized as potential COVID-19 treatments9–11. However, practical evidence, as well as working mechanisms, were not available. Here, we discern bioactivity among a group of lipid mediators on ACE2 expression, pro-inflammatory cytokines, and senescent proteins, which are critical targets related to SARS-CoV-2 entrance and deleterious consequences of this viral infection. We uncover that the lipid mediators ELV-N32 and RvD6i decrease ACE2 receptor expression and binding of RBD of the S protein, preventing enhancement of cytokine expression and senescence programming using a rat cornea in vivo model of alkali burn that induces a strong inflammatory reaction. Using HCEC in culture challenged with IFNγ, we found that ELV-N32 and RvD6i exert similar effects. In addition, ELV-N32 remarkably decreases Furin expression, a protease that cleaves the S1/S2 site required for SARS-CoV-2 entry in lung cells6.

A key cytokine responding to viral infections is IFNγ35, which increases in the serum of severely affected COVID-19 patients22,36. We found that IFNγ induces Ace2 expression in HCEC at a much lower dose than IFNα and increases the binding of the RBD to the cells. Moreover, IFNγ activates cellular senescence reflected in enhanced Cdkn2a expression and SASP secretome release. This observation could contribute to explaining why aging populations are more susceptible to COVID-1937. ELV-N32 does bear senolytic activity19, and both ELV-N32 and RvD6i suppressed senescence genes and SASP secretome in HCEC (Fig. 4d). Therefore, S protein internalization may lead to IFNγ secretion, which would synergize with an integrin-rich environment to amplify the IFNγ effect38 and stimulate Ace2 overexpression. As a result, the higher the ACE2, the higher the possibility of SARS-CoV-2 binding will be. ELV-N32 and RvD6i suppressed the IFNγ stimulation of Ace2 expression as well as the IFNγ-induced senescence, where many SASP components are pro-inflammatory cytokines. PEDF + DHA (the precursor of RvD6i) and RvD1 suppress type 1 pro-inflammatory macrophages (induced by IFNγ) while increasing the type 2 anti-inflammatory macrophage phenotype39,40. Interestingly, ELV-N32, RvD6i, and NPD1 attenuated the binding of ACE2-RBD in the IFNγ-treated cells in culture (Fig. 4c), while in the rat injured cornea, LXA4 displayed a significant effect on preventing ACE2-RBD interaction (Fig. 1f–h). Of the lipid mediators studied, ELV-N32 and RvD6i are the two most consistent lipid mediators displaying protective bioactivity. RvD6i was recently identified in mouse tears as related to corneal nerve regeneration17,41,42. ELV-N32 is a powerful neuroprotective and anti-inflammatory lipid mediator18.

Tissue damage is a serious complication of SARS-CoV-2-infected patients. Recently, Rosa et al. demonstrated that, in both tuberculosis and COVID-19 (two pulmonary diseases where neutrophils are associated with increased severity), there is an upregulation of neutrophil degranulation, innate immune response, ACE2 level, and IFNγ signaling pathways43. These results are similar to what we found in our cornea alkali-burn-damage model. Therefore, corneal alkali burn as a tissue damage model mimics the physical response of intestinal or lung epithelial cells during and after SARS-CoV-2 infection.

ACE2 is an anti-inflammatory factor44 and is also a SARS-CoV-2 receptor4. Thus, the increased abundance of ACE2 in damaged tissue, such as the lung or the cornea in this study, is a double-edged sword, especially when the anti-inflammatory activity is inadequate in diminishing the pro-inflammatory cytokines produced by the infection. The lipid mediators ELV-N32 and RvD6i might be an alternative way of providing anti-inflammatory activity. Even though the action of LXA4 or NPD1 was not consistent between in vitro and in vivo models, the potential of using lipid mediators to maintain the homeostasis after tissue damage is remarkable, especially in the current scenario in which the 'long COVID' (the long-lasting health effects of SARS-CoV-2 infection) is not well-documented.

ELV-N32 and RvD6i also decrease integrin expression. The S protein contains an RGD motif in the RBD site that recognizes integrins and stimulates virus internalization by activation PI-3K31,32, a pathway that the KEGG analysis from EnrichR tool predicted to increase along with ACE2 enhanced expression (Fig. 2c). The inhibition of integrin α5β1 by a non-RGD peptide derived from fibronectin prevents the binding of the S protein to ACE2 and decreases virus infection in vitro33.

Recently, Miner et al. showed that the human cornea does not support SARS-CoV-2 infection despite the expression of ACE2 in the human corneal epithelium45. However, studies in COVID-19 patients found an increase of the virus in dry eye disease, suggesting a possible consequence of infection46, and in a cohort of patients with COVID-19, 63% had a positive viral test in the conjunctiva, but the origin of the infection was undetermined47. Nevertheless, the role of lipid mediators in managing the ACE2 upregulation as well as hyper-inflammation, increase in cytokine expression, and senescence programming after tissue damage uncovers mechanistic insights that are also applicable to other tissues.

In conclusion, our data demonstrate that ELV-N32 or RvD6i diminish ACE2 expression and binding of the S protein RBD and, consequently, activate pro-homeostatic signaling and reduce tissue damage.

The application of these lipid mediators alone or as a complement with current antiviral strategies for COVID-19 could be of therapeutic use. Moreover, the lipid mediators identified here might work by similar mechanisms in other cell types and further expand the scope of their therapeutic applications.

Limitations of this study

Additional research will be needed to fully elucidate the molecular mechanisms by which the lipid mediators downregulate ACE2 and the genes encoding inflammatory/senescence proteins. The use of the full-length S protein or the pseudotype-virus that expresses SARS-CoV-2 S protein in the models studied here will provide insights into the molecular connection between lipid mediators acting on the cell attachment and cell entrance of the SARS-CoV-2 virus, particularly since ELV-N32 remarkably reduces furin expression correlated with ACE2 downregulation. Moreover, the use of the intact virus would offer a direct demonstration of the significance of the effects of the lipid mediators studied here.

Methods

Animals

Sprague–Dawley rats (8-week-old male) were obtained from Charles River Laboratories (Wilmington, MA, USA) and kept at the Animal Care of the Neuroscience Center of Excellence, Louisiana State University Health (LSUH; New Orleans, LA, USA). All animals were handled in compliance with the guidelines of the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research, and ARRIVE guidelines (https://arriveguidelines.org). The experimental protocol was approved by the Institutional Animal Care and Use Committee (IACUC) at LSUH.

Cornea injury

The rats were anesthetized by intraperitoneal injection of Ketamine (50–100 mg/kg) plus xylazine (5–10 mg/kg). A 4 mm diameter filter paper soaked in 1 N NaOH was placed on the central cornea of the right eye for 45 s, and then the eye was thoroughly washed with 10 mL of saline. After injury, the rats were randomly divided into five treatment groups: vehicle; lipoxin A4 (LXA4) from Cayman Chemical (Ann Arbor, MI, USA); R,R Resolvin D6 isomer (RvD6i), R,R neuroprotection D (NPD1), and elovanoid (ELV)-N32 synthesized by Dr. R. Nshimiyimana, T.F. Lam, and Prof. N. Petasis. All lipid solutions were prepared daily at the final concentration of 10 μM using PBS with the minimal contamination of ethanol by evaporating the ethanol and immediately dissolve the lipids in PBS, then vortex well for 2 min. Topical administration (20 μL) was done 3 ×/day for 14 days. To determine if the lipid have any side effects in the non-injured rat eye, eye drops at the same concentrations were used 3 ×/day for 1 week. The treatment did not produce blinking or rubbing of the eyes. There were no signs of conjunctiva hyperemia or edema using slit-lamp examination. The experiments were double-blinded with the lipid mediators coded during the whole experiments. At the end of the study, when all data was collected, the code was opened.

Antibodies

See Table 1.

Corneal RNA-sequencing

Injured corneas (n = 5/condition) were harvested and homogenized with TRIzol (ThermoFisher Scientific) on ice with a glass Dounce homogenizer. RNA sequencing was performed as described17. Briefly, after mRNA extraction and determination of purity, 8 ng of total RNA was reverse transcribed, and total cDNAs were amplified using ISPCR primer, and the library was made with the Nextera XT DNA library preparation kit (Illumina, San Diego, CA, USA). The libraries were pooled with the same molarity and sequenced using the NextSeq 500/550 High Output Kit v2 (75 cycles, Illumina). After demultiplexing, RNA-seq data were aligned to the Rattus Norvegicus reference genome (ftp://ftp.ensembl.org/pub/release-98/fasta/rattus_norvegicus/dna/) using the Subread package v2.0.1 alignment function48. The BAM files for sequencing data alignment were counted using featureCounts function of Subread tool49 using the macOS Catalina. The raw count data were subjected to differential gene expression analysis using DESeq2 package for R50 with the vehicle group as reference. The adjusted p-values were named as the false discover rate (FDR). Significantly changed genes (FDR < 0.05) between each treatment vs. vehicle were subjected to the enrichment analysis using EnrichR51 and NetworkAnalyst 3.052, and pathway analysis using the IPA (Qiagen Inc., https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis).

Preparation of Alexa 594-conjugated RBD fragment of S protein

RBD fragment of the Spike protein belonging to SARS-CoV-2 (Raybiotech, Peachtree Corners GA. Cat. 230-30162-1000) was labeled using Alexa Fluor 594 Protein Labeling Kit (ThermoFisher Scientific, Waltham, MA. Cat. A10239) following the manufacturer's directions. Briefly, 1 mg of protein was dissolved in 0.1 M bicarbonate and then incubated with the Alexa Fluor 594 dye for one hour. The dye was washed using an Amicon-Ultra centrifugal filter cutoff 10 kDa (Merck, Millipore Carrigtwohill, CO. Cat. UFC201024). To assess the efficiency of the label, the protein was measured at 280 nm and 590 nm absorbance using NanoDrop One (ThermoFisher Scientific). There was a ratio of 0.4 mol of dye/mole of protein and a recovery of about 80%.

Human corneal epithelial cells (HCEC) culture

All experiments with human corneal epithelial cells were approved by the Institutional Review Board of LSUHNO and conducted in accordance with NIH guidelines. The HCEC were obtained by Dr. Roger Beuerman using an HPV16-E6E7 vector and were kept frozen in the laboratory at passage 2553. Cells were maintained in keratinocyte growth (KGM) medium containing the keratinocyte basal medium (KBM) (Lonza: CC-3101) supplemented with bovine pituitary extract (BPE), hEGF, Insulin, Hydrocortisone and Gentamicin Sulfate-Amphotericin (GA-1000) (Lonza, Cat. CC-4131). For all experiments, cells were seeded at 30,000 cells/cm2.

For screening the stimulation of receptor ACE2 by cytokines, the HCEC were cultured with KGM until 50–60% confluence. Then, changed to KBM containing IL-1β, -2, -6 and 8, IFN-α, -ε, and -γ or TNFα at 1, 10 or 100 ng/mL. The cells were harvested after 6 h and analyze for the gene expression of Ace2. In other experiments, HCEC were stimulated with IFNγ, and thereafter, lipid mediators were added. For the Alexa 594-conjugated RBD binding, IFNγ was used as a cytokine trigger. At 12 h after cytokine exposure and lipid mediator treatments, 0.5 μg of labeled RBD was added to the medium. The evaluation of RBD binding was conducted 24 h after.

Immunohistochemistry

Corneal tissue was fixed in Zamboni fixative (MasterTech Scientific, Lodi, CA USA) for 2 h immediately after euthanasia. After thoroughly washing with PBS, the corneas were embedded in optimal cutting temperature compound, and serial 10-μm cryostat sections were obtained, dried at room temperature for 2 h, and stored at − 20 °C until use. For immunofluorescence, the sections were incubated with primary antibodies at the concentration described in Table 1 in a wet chamber at 4 °C overnight. The sections were washed 3 ×/5 min with PBS following by incubation for 1 h at RT with Alexa Fluor-conjugated secondary antibodies (1:1000 dilution). All sections were counterstained with DAPI (ThermoFisher Scientific, Cat. D1306), and images of rat corneal samples were acquired with an Olympus IX71 fluorescent microscope.Table 1 List of primary antibodies used in this study.

No.	Name	Company	Cat. number	Immunofluorescence	Western blot	
1	Rabbit anti-ACE2	Abcam	Ab108252	1:1000	1:100	
2	Rabbit anti-DPP4	Abcam	Ab129060	1:500	1:100	
3	Rabbit anti-FURIN	Abcam	Ab183495	1:1000	1:100	
4	Rabbit anti-TMPRSS2	Abcam	Ab109131	1:1500	1:100	
5	Rabbit anti-GAPDH	Santa Cruz Biotechnology	Sc-25778		1:1000	
6	Anti-neutrophil	LSBio	LS-C348005	1:500		
7	Mouse anti-rat CD68	Bio-Rad	MCA341GA	1:1000		
8	Rabbit polyclonal to IL-1 beta	Abcam	Ab9722		1:100	
9	Rabbit polyclonal to IL-6	Abcam	Ab6672		1:100	
10	Rabbit polyclonal to MMP14	Abcam	Ab53712		1:100	

Unbiased imaging-based evaluation of RBD binding

Twenty-four hours after Alexa 594-RBD was added to the HCEC, the cells were washed with PBS (3 ×/5 min) and fixed with 4% paraformaldehyde for 30 richardchavez@example.net. The HCEC were washed 2 × with PBS and stained with Hoechst 33342 Solution (ThermoFisher Scientific, Cat. 62249) for 30 richardchavez@example.net. Next, the HCEC were washed 2 × with PBS before imaging. For unbiased data collection, 7 designated areas were defined in each well (Supplementary Fig. S7) and captured with an Olympus FV3000 confocal laser scanning microscopy under "Multi Area Time Lapse" (MATL) mode. All images were acquired with the same parameters and Z-section range, converted and inputted in the Imaris software version 9.5.1. The threshold for the control images was defined by the HCEC without Alexa 594-conjugated RBD of S protein and using it as a threshold filter for the Imaris batch image processing function. The sum of total intensity for each image was used to evaluate the binding efficiency. The whole process was summarized in Supplementary Fig. S7b,c.

Droplet digital PCR (dd-PCR)

Total RNA was isolated using RNeasy Plus Mini Kit (Qiagen, Germany), and 1 µg of total RNA was reverse transcribed using an iScript cDNA Synthesis Kit (Bio-Rad, Cat. 170–8841). For ddPCR, 10 ng of cDNA was multiplexed with Ace2 and phosphoglycerate kinase 1 (Pgk1) probes (Bio-Rad, Cat. qHSACEP005-1563 and dHSACPE503-3809) using dd-PCR Supermix for Probes No dUTP (Bio-Rad, Cat. 1863024). Then, 20 µL of the reaction was mixed with 70 µL of Droplet Generation Oil (Bio-Rad Cat. 1863005) to make the reaction droplets. The emulsified samples were carefully transferred to PCR plates (Bio-Rad, Cat. 12001925) and amplified using the cycling: 95 °C for 10 min, 40 cycles of a two-step cycling protocol (94 °C for 30 s and 60 °C for 1 min), and 98 °C for 10 min. Next, the post-cycling plate was placed into the QX200 Droplet Reader with the FAM/HEX setting. The absolute quantity of DNA per sample (copies/µL) was processed using QuantaSoft Analysis Pro Software. For the data analysis, the ratio of quantified Ace2 to Pgk1 was used.

Capillary-based western blot

The capillary-based western assay was performed using a Jess system (Protein Simple, San Jose, CA, USA) as manufacture suggested protocol. Briefly, samples were lysed with RIPA buffer containing a protease inhibitor cocktail (Sigma, Cat. P8340). Cell debris was removed after 10 min centrifugation at 16,000×g. Protein concentration was determined by BCA assay (ThermoFisher Scientific, Cat. 23225) and 1 µg was used/reaction. Fluorescent Master Mix was mixed with 40 mM DTT, and the mixture was added to each sample (1 µg/5 µL) to provide a denaturing and reducing environment. Samples were heated at 95 °C/5 min, and 3 µL of each sample (0.6 µg of total protein) were loaded. The 12–230 kDa cartridge (Protein Simple, #SM-W004) was used. Primary antibodies were diluted in antibody diluent 2 buffer (Protein Simple, #042-203) while the working solution of secondary antibodies was provided by the company (Protein Simple, #042-206). Then, the filled plate was spin-down for 10 min at 1000×g to remove bubbles and plate, and capillaries were loaded into the Jess machine. For data analysis, the area of spectra that matched the molecular weight of the target protein was used. To reduce the coefficient variant, we analyzed the GAPDH for each capillary. The ratio of the targeted protein to GAPDH was used for statistical comparisons. For visualization, the artificial lanes generated from spectra volume was used.

High-throughput qPCR using Biomark HD

Quantitative PCR was performed with the Biomark HD system (Fluidigm, San Francisco, CA, USA). Briefly, 200 ng of RNA was reverse-transcribed using iScript Reverse Transcription Supermix (Bio-Rad), and the cDNA was pre-amplified using the PreAmp Master Mix (PN 100-5580; Fluidigm). The cDNA was then subjected to Exonuclease I treatment and diluted 5 times in TE Buffer. The qPCR reaction mixture and primer reaction mixture were made and loaded into the Biomark 96.96 IFC (Integrated Fluidic Circuit). The enzyme reaction was mixed using Juno Controller (Fluidigm) and run using the cycling program of (i) 70 °C for 40 min followed by 60 °C for 30 s, (ii) hot start for 1 min at 95 °C, (iii) 30 cycles of denaturation at 96 °C for 5 s, and annealing at 60 °C for 20 s, and (iv) melting curves between 60 °C and 95 °C with 1 °C increments/3 s. The Ct value of target genes was normalized to the house-keeping genes Gapdh, Hprt1, and Tfrc before normalized to the vehicle group. Relative fold changes from the ΔΔCT calculation was used to make the graph. Primer sequences are provided in Table 2.Table 2 Primers for qPCR.

Gene name	Forward	Reverse	
Ace2	CATTGGAGCAAGTGTTGGATCTT	GAGCTAATGCATGCCATTCTCA	
Cdkn2a	GGGGGCACCAGAGGCAGT	GGTTGTGGCGGGGGCAGTT	
Mmp1	GGGCTTGAAGCTGCTTACGAATT	CAGCATCGATATGCTTCACAGTTCT	
Gapdh	TGGACCTGACCTGCCGTCTA	CCCTGTTGCTGTAGCCAAATTC	
Tfrc	GGCTACTTGGGCTATTGTAAAGG	CAGTTTCTCCGACAACTTTCTCT	
Hprt1	GACCAGTCAACAGGGGACAT	AACACTTCGTGGGGTCCTTTTC	

Statistical analysis

Data are expressed as mean ± SD. The data were analyzed by 1-way ANOVA followed by Dunnett's multiple comparisons post hoc test at 95% confidence level with the vehicle as reference. All graphs were made using GraphPad Prism 7 (GraphPad Software, La Jolla, CA, USA) with the mean ± SD, while all statistical analyses were done using the built-in function of Prism 7.

Supplementary Information

Supplementary Figures.

Supplementary Information

The online version contains supplementary material richardchavez@example.net/s41598-021-92293-x.

Acknowledgements

The authors are grateful to Drs. Jovanny Zabaleta and Jone Garai (Louisiana Cancer Research Center Translational Genomics Core) for advice with RNA-seq library preparation and sequencing run. This work was supported by National Eye Institute Grants R21 EY031031 (H.E.P.B. and J.H.) and R01 EY019465 (to H.E.P.B.) and by an Institutional Grant from the School of Medicine, LSUHSC (to N.G.B.).

Author contributions

H.E.P.B., N.G.B, and T.L.P. designed the experiments. T.L.P. performed acquisition and analysis of data, writing, and critical review of the manuscript; J.H. did the injury, treatments, isolation of rat tissues, and immunohistochemistry. A.H.K. coded and prepared the drugs, maintained the HCEC, and helped with RNA extraction. J.C. prepared Alexa 594-conjugated RBD fragment of SARS-CoV-2 Spike. K.V.D. did the HCEC RNA extraction, ddPCR analysis, and SASP Secretome (β-Gal staining) of HCEC. T.F.L., R.N. and N.A.P. synthesized ELV-N32, NPD1, and RvD6i. H.E.P.B. and N.G.B supervised the study and wrote the manuscript.

Data availability

The data that support the findings of this study are available from the corresponding authors upon reasonable request.

Competing interests

The authors declare no competing interests.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Naming the coronavirus disease (COVID-19) and the virus that causes it. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it.
2. Zhu N A novel coronavirus from patients with pneumonia in China, 2019 N. Engl. J. Med. 2020 382 727 283-13-3986/NEJMoa2001017 31978945
3. Chen N Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study Lancet 2020 395 507 283-13-3986/S0140-6736(20)30211-7 32007143
4. Hoffmann M SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Cell 2020 181 271 280.e8 10.1016/j.cell.2020.02.052 32142651
5. Li Y The MERS-CoV receptor DPP4 as a candidate binding target of the SARS-CoV-2 spike iScience 2283-13-398660 10.1016/j.isci.2020.101160 32405622
6. Hoffmann M Kleine-Weber H Pöhlmann S A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells Mol. Cell 2020 78 779 784.e5 10.1016/j.molcel.2020.04.022 32362314
7. Sungnak W SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes Nat. Med. 2020 26 681 283-13-3986/s41591-020-0868-6 32327758
8. Zhou L ACE2 and TMPRSS2 are expressed on the human ocular surface, suggesting susceptibility to SARS-CoV-2 infection Ocul. Surf. 2020 18 537 283-13-3986/j.jtos.2020.06.007 32544566
9. Panigrahy D Inflammation resolution: A dual-pronged approach to averting cytokine storms in COVID-19? Cancer Metastasis Rev. 2283-13-3986/s10555-020-09889-4 32385712
10. Regidor P-A Covid-19 management with inflammation resolving mediators? Perspectives and potential Med. Hypotheses 2020 142 109283-13-3986/j.mehy.2020.109813 32416413
11. Das UN Can bioactive lipids inactivate coronavirus (COVID-19)? Arch. Med. Res. 2020 51 282 283-13-3986/j.arcmed.2020.03.004 32229155
12. Das UN Response to: Bioactive lipids and coronavirus (COVID-19)-further discussion Arch. Med. Res. 2020 51 445 283-13-3986/j.arcmed.2020.04.004 32345532
13. Serhan CN Pro-resolving lipid mediators are leads for resolution physiology Nature 2014 510 92 283-13-3986/nature13479 24899309
14. Serhan CN Hamberg M Samuelsson B Lipoxins: Novel series of biologically active compounds formed from arachidonic acid in human leukocytes Proc. Natl. Acad. Sci. 1984 81 5335 5283-13-3986/pnas.81.17.5335 6089195
15. Bazan NG Docosanoids and elovanoids from omega-3 fatty acids are pro-homeostatic modulators of inflammatory responses, cell damage and neuroprotection Mol. Aspects Med. 2018 64 18 33 10.1016/j.mam.2018.09.003 30244005
16. Mukherjee PK Marcheselli VL Serhan CN Bazan NG Neuroprotectin D1: A docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress Proc. Natl. Acad. Sci. U.S.A. 2004 101 8491 8283-13-3986/pnas.0402531101 15152078
17. Pham TL Novel RvD6 stereoisomer induces corneal nerve regeneration and wound healing post-injury by modulating trigeminal transcriptomic signature Sci. Rep. 2283-13-3986 10.1038/s41598-020-61390-8 32165657
18. Jun B Elovanoids are novel cell-specific lipid mediators necessary for neuroprotective signaling for photoreceptor cell integrity Sci. Rep. 2017 7 5283-13-3986/s41598-017-05433-7 28706274
19. Do KV Elovanoids counteract oligomeric β-amyloid-induced gene expression and protect photoreceptors Proc. Natl. Acad. Sci. U.S.A. 2019 116 24317 24283-13-3986/pnas.1912959116 31712409
20. Ziegler CGK SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues Cell 2020 181 1016 1035.e19 10.1016/j.cell.2020.04.035 32413319
21. Wu P Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei Province, China JAMA Ophthalmol. 2283-13-3986/jamaophthalmol.2020.1291 32232433
22. Huang C Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Lancet Lond. Engl. 2020 395 497 283-13-3986/S0140-6736(20)30183-5
23. Pedersen SF Ho Y-C SARS-CoV-2: A storm is raging J. Clin. Investig. 2020 130 2202 2283-13-3986/JCI137647 32217834
24. Sotozono C Cytokine expression in the alkali-burned cornea Curr. Eye Res. 1997 16 670 283-13-3986/ceyr.16.7.670.5057 9222084
25. Coppé J-P Desprez P-Y Krtolica A Campisi J The senescence-associated secretory phenotype: The dark side of tumor suppression Annu. Rev. Pathol. 2010 5 99 283-13-3986/annurev-pathol-121808-102144 20078217
26. Olagnier D SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate Nat. Commun. 2283-13-3986 10.1038/s41467-020-18764-3 33009401
27. Yang Y Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19 J. Allergy Clin. Immunol. 2020 146 119 127.e4 10.1016/j.jaci.2020.04.027 32360286
28. Marten NW Zhou J The role of metalloproteinases in corona virus infection Exp. Models Mult. Scler. 2283-13-3986/0-387-25518-4_48
29. Ueland T Distinct and early increase in circulating MMP-9 in COVID-19 patients with respiratory failure J. Infect. 2283-13-3986/j.jinf.2020.06.061 32603675
30. Bose P Bathri R Kumar L Vijayan VK Maudar KK Role of oxidative stress and transient receptor potential in chronic obstructive pulmonary disease Indian J. Med. Res. 2015 142 245 283-13-3986/0971-5916.166529 26458340
31. Luan J Lu Y Gao S Zhang L A potential inhibitory role for integrin in the receptor targeting of SARS-CoV-2 J. Infect. 2283-13-3986/j.jinf.2020.03.046 32283163
32. Sigrist CJ Bridge A Le Mercier P A potential role for integrins in host cell entry by SARS-CoV-2 Antiviral Res. 2020 177 104283-13-3986/j.antiviral.2020.104759 32130973
33. Beddingfield B The integrin binding peptide, ATN-161, as a novel therapy for SARS-CoV-2 infection bioRxiv 2283-13-3986/230.283-13-398687 32587964
34. Serhan CN Chiang N Dalli J The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution Semin. Immunol. 2015 27 200 283-13-3986/j.smim.2015.03.004 25857211
35. Samuel CE Antiviral actions of interferons Clin. Microbiol. Rev. 2001 14 778 283-13-3986/CMR.14.4.778-809.2001 11585785
36. Han H Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors Emerg. Microbes Infect. 2020 9 1123 1283-13-3986/22221751.2020.1770129 32475230
37. CDC. Coronavirus Disease 2019 (COVID-19). Centers for Disease Control and Prevention https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-increased-risk.html (2020).
38. Krummel MF Paracrine costimulation of IFN-γ signaling by integrins modulates CD8 T cell differentiation Proc. Natl. Acad. Sci. U.S.A. 2018 115 11585 11283-13-3986/pnas.1804556115 30348790
39. Schmid M Gemperle C Rimann N Hersberger M Resolvin D1 polarizes primary human macrophages toward a proresolution phenotype through GPR32 J. Immunol. (Baltim. Md.) 2016 1950 196 3429 3437
40. He J Pham TL Kakazu A Bazan HEP Recovery of corneal sensitivity and increase in nerve density and wound healing in diabetic mice after PEDF plus DHA treatment Diabetes 2283-13-3986 2283-13-3986/db17-0249 28592408
41. Pham TL Defining a mechanistic link between pigment epithelium-derived factor, docosahexaenoic acid, and corneal nerve regeneration J. Biol. Chem. 2017 292 18486 18283-13-3986/jbc.M117.801472 28972155
42. Pham TL Bazan HEP Docosanoid signaling modulates corneal nerve regeneration: Effect on tear secretion, wound healing, and neuropathic pain J. Lipid Res. 2283-13-3986/jlr.TR120000954 32404333
43. Rosa BA IFN signaling and neutrophil degranulation transcriptional signatures are induced during SARS-CoV-2 infection bioRxiv 2283-13-3986/230.283-13-398698 32793903
44. Rodrigues Prestes TR Rocha NP Miranda AS Teixeira AL Simoes-E-Silva AC The anti-inflammatory potential of ACE2/angiotensin-(1–7)/Mas receptor axis: Evidence from basic and clinical research Curr. Drug Targets 2283-13-3986 1283-13-3986/1389450117666160727142401 27469342
45. Miner JJ HSV-1 and Zika virus but not SARS-CoV-2 replicate in the human cornea and are restricted by corneal type III interferon Cell Rep. 2283-13-398639 10.1016/j.celrep.2020.108339 33147451
46. Gambini G Ocular surface impairment after COVID-19: A cohort study Cornea 2283-13-3986/ICO.0000000000002643
47. Azzolini C SARS-CoV-2 on ocular surfaces in a cohort of patients with COVID-19 from the lombardy region, Italy JAMA Ophthalmol. 2283-13-3986/jamaophthalmol.2020.5464 33662099
48. Liao Y Smyth GK Shi W The Subread aligner: Fast, accurate and scalable read mapping by seed-and-vote Nucleic Acids Res. 2013 41 e283-13-3986/nar/gkt214 23558742
49. Liao Y Smyth GK Shi W featureCounts: An efficient general purpose program for assigning sequence reads to genomic features Bioinformatics (Oxf., Engl.) 2014 30 923 930 10.1093/bioinformatics/btt656
50. Love MI Huber W Anders S Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 Genome Biol. 2014 15 283-13-3986/s13059-014-0550-8 25516281
51. Kuleshov MV Enrichr: A comprehensive gene set enrichment analysis web server 2016 update Nucleic Acids Res. 2016 44 W90 97 10.1093/nar/gkw377 27141961
52. Zhou G NetworkAnalyst 3.0: A visual analytics platform for comprehensive gene expression profiling and meta-analysis Nucleic Acids Res. 2019 47 W234 W283-13-3986/nar/gkz240 30931480
53. Sharma GD Kakazu A Bazan HEP Protein kinase C alpha and epsilon differentially modulate hepatocyte growth factor-induced epithelial proliferation and migration Exp. Eye Res. 2007 85 289 283-13-3986/j.exer.2007.05.004 17603037


{'source': 'PubMedDataset'}